Company intelligence / Profile preview

SemBioSys Genetics

Calgary, Alberta, Canada

Ownership: Private
Employees: ~20
Development stage: Other

Overview

SemBioSys demonstrated in a Phase 1/2 clinical trial that its plant-produced biosimilar insulin (SBS-1000) was bioequivalent to humulin. Preclinical development of Apo AI(Milano) was reported. No subsequent advanced clinical or commercial activities; company wound down after failed partnership attempts.[3][4][6]

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Recombinant proteinBiologic
Industry: Biotech

Drug pipeline

1 asset

apolipoprotein A-I

Preclinical

Partnerships

Martek Biosciences CorporationLonza Inc.Arcadia BiosciencesDow AgroSciences (animal vaccine feasibility)Tasly Pharmaceuticals (unconsummated joint venture, terminated 2012)[3][6]

Beyond the preview

Go deeper on SemBioSys Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SemBioSys Genetics.

Explore the full profile